ELISA/assay

Rat Nuclear factor-kappa B, NF- degree B ELISA Kit

MBS703405

48-Strip-Wells

565 USD

ELISA Kit

Rat Nuclear factor-kappa B, NF- degree B ELISA Kit

nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

Rat Nuclear factor-kappa B (NF-kappaB) ELISA Kit; DKFZp686C01211; EBP-1; KBF1; MGC54151; NF-kappa-B; NF-kappaB; NFKB-p105; NFKB-p50; p105; p50; DNA binding factor KBF1; NF-kappabeta; nuclear factor NF-kappa-B p50 subunit; nuclear factor kappa-B DNA bi; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1

Nuclear factor NF-kappa-B p105 subunit; Nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p105 subunit; DNA-binding factor KBF1; nuclear factor of kappa light chain gene enhancer in B-cells 1, p105; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, p105; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; DNA-binding factor KBF1; EBP-1; Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1Cleaved into the following chain:Nuclear factor NF-kappa-B p50 subunit

NFKB1

Nfkb1; Nfkb1; EBP-1; NF-kB

NFKB1_RAT

Rat

522

This assay has high sensitivity and excellent specificity for detection of rat NF-kB. No significant cross-reactivity or interference between rat NF-kB and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma and tissue homogenates. Assay Type: Sandwich. Detection Range: 1.56 pg/ml -100 pg/ml. Sensitivity: The minimum detectable dose of rat NF-kB is typically less than 0.39 pg/ml. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay Precision: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for NF-kappaB has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any NF-kappaB present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for NF-kappaB is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of NF-kappaB bound in the initial step. The color development is stopped and the intensity of the color is measured.

2500134

Q63369.1

Q63369

56,554 Da

Activated TLR4 Signalling Pathway (1010983); Activation Of NF-kappaB In B Cells Pathway (1010940); Acute Myeloid Leukemia Pathway (83505); Acute Myeloid Leukemia Pathway (529); Adaptive Immune System Pathway (1010925); Adipocytokine Signaling Pathway (83485); Adipocytokine Signaling Pathway (505); Amoebiasis Pathway (167311); Amoebiasis Pathway (167191); Apoptosis Pathway (219785)

gene encodes a 105 kD protein that can be processed to create a 50 kD protein; the larger protein is a Rel protein-specific transcription inhibitor and the smaller protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex [RGD, Feb 2006]

Function: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. Plays a role in the regulation of apoptosis. Isoform 5, isoform 6 and isoform 7 act as inhibitors of transactivation of p50 NF-kappa-B subunit, probably by sequestering it in the cytoplasm. Isoform 3 (p98) (but not p84 or p105) acts as a transactivator of NF-kappa-B-regulated gene expression. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105

48-Strip-Wells

565 USD

96-Strip-Wells

810

5x96-Strip-Wells

2750

10x96-Strip-Wells

5150